WO2006020557A3 - Procedes d'utilisation ou d'identification d'agents inhibant la croissance d'un cancer - Google Patents

Procedes d'utilisation ou d'identification d'agents inhibant la croissance d'un cancer Download PDF

Info

Publication number
WO2006020557A3
WO2006020557A3 PCT/US2005/028100 US2005028100W WO2006020557A3 WO 2006020557 A3 WO2006020557 A3 WO 2006020557A3 US 2005028100 W US2005028100 W US 2005028100W WO 2006020557 A3 WO2006020557 A3 WO 2006020557A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
identifying agents
cancer growth
inhibit cancer
directed
Prior art date
Application number
PCT/US2005/028100
Other languages
English (en)
Other versions
WO2006020557A2 (fr
Inventor
Li Henry Qi-Xian
Ning Ke
Mirta Grifman
Wufang Fan
Yu Dehua
Flossie Wong-Staal
Original Assignee
Immusol Inc
Li Henry Qi-Xian
Ning Ke
Mirta Grifman
Wufang Fan
Yu Dehua
Flossie Wong-Staal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immusol Inc, Li Henry Qi-Xian, Ning Ke, Mirta Grifman, Wufang Fan, Yu Dehua, Flossie Wong-Staal filed Critical Immusol Inc
Publication of WO2006020557A2 publication Critical patent/WO2006020557A2/fr
Publication of WO2006020557A3 publication Critical patent/WO2006020557A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne, de manière générale, des procédés d'inhibition de la croissance de cellules cancéreuses ou de tumeurs. Cette invention concerne également l'identification d'agents utiles dans le traitement du cancer. Ces procédés impliquent généralement le ciblage de deux gènes ou de leurs protéines codées, GPR56 ou DNER.
PCT/US2005/028100 2004-08-10 2005-08-09 Procedes d'utilisation ou d'identification d'agents inhibant la croissance d'un cancer WO2006020557A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60064704P 2004-08-10 2004-08-10
US60/600,647 2004-08-10

Publications (2)

Publication Number Publication Date
WO2006020557A2 WO2006020557A2 (fr) 2006-02-23
WO2006020557A3 true WO2006020557A3 (fr) 2007-08-16

Family

ID=35908070

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/028100 WO2006020557A2 (fr) 2004-08-10 2005-08-09 Procedes d'utilisation ou d'identification d'agents inhibant la croissance d'un cancer

Country Status (1)

Country Link
WO (1) WO2006020557A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012157589A1 (fr) * 2011-05-13 2012-11-22 国立大学法人宮崎大学 Inhibiteur d'adhérence cellulaire, inhibiteur de prolifération cellulaire, et méthode et trousse pour le dépistage du cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030167485A1 (en) * 1997-09-24 2003-09-04 Garvan Institute Of Medical Research Novel G protein-coupled receptor encoding gene and diagnostic uses therefor
US20030175209A1 (en) * 2001-12-27 2003-09-18 Sabine Mueller Use of biomolecular targets in the treatment and visualization of tumors
US20040259247A1 (en) * 2000-12-01 2004-12-23 Thomas Tuschl Rna interference mediating small rna molecules

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030167485A1 (en) * 1997-09-24 2003-09-04 Garvan Institute Of Medical Research Novel G protein-coupled receptor encoding gene and diagnostic uses therefor
US20040259247A1 (en) * 2000-12-01 2004-12-23 Thomas Tuschl Rna interference mediating small rna molecules
US20030175209A1 (en) * 2001-12-27 2003-09-18 Sabine Mueller Use of biomolecular targets in the treatment and visualization of tumors

Also Published As

Publication number Publication date
WO2006020557A2 (fr) 2006-02-23

Similar Documents

Publication Publication Date Title
WO2006124892A3 (fr) Modulateurs de la toxicite induite par l'alpha-synucleine
WO2007011962A3 (fr) Traitement du cancer
WO2006014729A3 (fr) Inhibiteurs de la proteine 4 de type angiopoietine, combinaisons correspondantes et leur utilisation
WO2004113571A3 (fr) Genes specifiques de la prostate et leur utilisation comme cibles dans le traitement et le diagnostic du cancer de la prostate
WO2006020722A3 (fr) Compositions pharmaceutiques de beta-lapachone et d'analogues de beta-lapachone possedant un potentiel de ciblage de tumeur ameliore
HK1202437A1 (en) Selected antibody bound to anionic phospholipid and aminophospholipid, therapeutic uses thereof
WO2008076278A8 (fr) Procédés de traitements
TW200621240A (en) Cancer treatments
WO2006028655A3 (fr) Genes, compositions, kits, et methodes pour identification, evaluation, prevention et therapie du cancer de la prostate
WO2008030883A3 (fr) Traitement du cancer
EA200602100A1 (ru) Соединения и способы для ингибирования митотической прогрессии
SG160412A1 (en) Anti-igfr1 antibody therapeutic combinations
WO2006133271A3 (fr) Compositions et methodes portant sur une therapie photodynamique ciblee
WO2002080754A3 (fr) Methodes d'utilisation d'une annexine permettant de visualiser la mort cellulaire in vivo et de traiter des etats pathologiques
WO2006004833A3 (fr) Inhibiteurs de kinase a base de pyrrolotriazine
WO2006102504A3 (fr) Combinaisons destinees au traitement de cancer
WO2007038868A3 (fr) Nouveau compose d'enediyne et ses utilisations
WO2006113483A3 (fr) Methodes et compositions pour le traitement ou la prevention du cancer
UA90698C2 (en) Triazole substituted aminobenzophenone compounds
WO2006009765A3 (fr) Procedes d'identification et d'utilisation de composes adaptes au traitement de cellules cancereuses resistantes aux medicaments
UA84954C2 (ru) Конденсированные пиримидоны, пригодные для лечения и профилактики злокачественного новообразования
WO2006091542A3 (fr) Utilisation du sildenafil, du vardenafil et d'autres inhibiteurs de la 5-phosphodiesterase pour augmenter la permeabilite d'une barriere sang /cerveau anormale
WO2007112316A3 (fr) Immunothérapie mycobactérienne destinée au traitement du cancer
WO2008083326A3 (fr) Thérapie antitumorale par ciblage de ews-fli1
WO2007019308A3 (fr) Analogues d'illudine utiles en tant qu'agents anticancereux

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase